Pennsylvania biotech Ocugen advances a modifier gene therapy approach that resets retinal cellular networks rather than replacing individual mutations, positioning OCU400 to address up to 300,000 RP patients in the U.S. and Europe—far beyond the 1-2% eligible for current mutation-specific
Founded just three months ago in August 2025, London-based Kindling Bio is inverting the standard adult-to-child drug translation model by developing a gene therapy platform designed specifically for childhood solid tumors from the outset. With £250k in launch funding and
Norwegian Biotech Secures FDA IND Clearance for Novel Mechanism in Brain Cancer Norwegian biotech Hemispherian brings a distinctive approach to glioblastoma treatment with GLIX1, a first-in-class small-molecule TET2 agonist that recently cleared an IND with the U.S. FDA. CEO Zeno
New Jersey biotech Citius Pharmaceuticals is transitioning from a development-stage company to revenue generation as it prepares to commercially launch LYMPHIR™, the only FDA-approved IL-2R-targeted systemic therapy for cutaneous T-cell lymphoma, in Q4 2025. In this interview, the CEO Leonard
Swedish biotech VERIGRAFT outlines how it solved regenerative medicine’s manufacturing paradox, creating the first tissue therapy platform designed for industrial-scale production while maintaining patient personalisation. Founded in Gothenburg in 2014, VERIGRAFT has achieved what many considered impossible in regenerative medicine: developing
Atlanta-based biotech GeoVax outlines how its multi-antigen MVA platform addresses critical gaps left by single-antigen vaccines, with three Phase 2 COVID-19 trials underway and a Phase 3 Mpox vaccine trial scheduled for H2 2026 Founded in 2001 from Emory University’s
French biotech Ciloa outlines how 14 years of exosome engineering trials led to breakthrough adiponectin biotherapeutic now advancing toward Phase I trials in 2027. CEO Robert Z. Mamoun describes the transition from retrovirus research to developing what the company claims
Paris biotech One Biosciences outlines how single-cell transcriptomics can transform precision oncology by capturing the cellular complexity that traditional bulk sequencing misses. Founded by Institut Curie pioneer Dr. Céline Vallot, the company has secured over €20 million to bring OneMap™
Irish biotech Priothera is advancing mocravimod, a non-immunosuppressive S1P receptor modulator that the founding team rescued from Novartis’ pipeline, now targeting improved survival outcomes for AML patients undergoing stem cell transplantation. Co-founder Dr. Simone Seiter outlines how strategic protocol amendments
Swedish biotech Alligator Bioscience outlines how strategic antibody engineering and focused execution positioned mitazalimab for pivotal trials in metastatic pancreatic cancer, transforming from university research into a Phase 3-ready immunotherapy program. Founded in 2001 and headquartered in Lund, Sweden, Alligator
